However, based on its high diagnostic accuracy, clinical utility, and recent approval by the US Food and Drug Administration for the detection of PCA, PSMA-PET/CT is expected to contribute significantly to the diagnostic process of primary PCA in the future. The gene discussed is FOLH1; the disease is posterior cortical atrophy.